Barclays PLC Cuts Position in Avantor, Inc. (NYSE:AVTR)

Barclays PLC lessened its stake in Avantor, Inc. (NYSE:AVTRFree Report) by 20.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 452,651 shares of the company’s stock after selling 117,243 shares during the quarter. Barclays PLC owned 0.07% of Avantor worth $9,540,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AVTR. Jump Financial LLC purchased a new position in shares of Avantor in the 3rd quarter valued at about $314,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Avantor by 11.6% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 298,558 shares of the company’s stock valued at $6,294,000 after purchasing an additional 31,060 shares in the last quarter. Sivik Global Healthcare LLC increased its stake in shares of Avantor by 140.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 180,000 shares of the company’s stock valued at $3,794,000 after purchasing an additional 105,000 shares in the last quarter. Schechter Investment Advisors LLC increased its stake in shares of Avantor by 27.0% in the 3rd quarter. Schechter Investment Advisors LLC now owns 21,852 shares of the company’s stock valued at $461,000 after purchasing an additional 4,652 shares in the last quarter. Finally, Sound Shore Management Inc CT increased its stake in shares of Avantor by 19.1% in the 3rd quarter. Sound Shore Management Inc CT now owns 3,989,327 shares of the company’s stock valued at $84,095,000 after purchasing an additional 639,715 shares in the last quarter. Institutional investors and hedge funds own 89.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AVTR shares. Evercore ISI upgraded Avantor from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $19.50 to $26.00 in a research note on Thursday, January 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on Avantor from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Tuesday, December 12th. The Goldman Sachs Group boosted their price objective on Avantor from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, December 7th. Wolfe Research initiated coverage on Avantor in a research note on Wednesday, December 13th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 price objective on shares of Avantor in a research note on Tuesday, January 9th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Avantor has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Get Our Latest Analysis on Avantor

Avantor Trading Down 0.3 %

AVTR opened at $23.65 on Wednesday. Avantor, Inc. has a one year low of $16.63 and a one year high of $25.25. The stock has a market capitalization of $16.00 billion, a PE ratio of 43.80, a P/E/G ratio of 1.41 and a beta of 1.36. The business’s 50 day moving average price is $22.24 and its 200 day moving average price is $21.17. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.03 and a current ratio of 1.60.

Avantor Profile

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Recommended Stories

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.